Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights
The combination of copanlisib and niraparib demonstrated limited tolerability, and the objective response rate was modest. However, functional proteomic analyses identified candidate biomarkers-particularly Akt pathway substrates-which may inform future strategies to optimize PI3K and PARP inhibitor combinations.
Authors
- Amir A. Jazaeri (ORCID: https://orcid.org/0000-0003-4335-4151)
- Jun Yao (ORCID: https://orcid.org/0000-0001-7993-6714)
- Aaron Shafer (ORCID: https://orcid.org/0000-0003-2565-0264)
- Shannon N. Westin (ORCID: https://orcid.org/0000-0002-1922-0156)
- S. J. Lee
- Joseph Celestino (ORCID: https://orcid.org/0000-0002-7758-1558)
- Michaela Onstad Grinsfelder (ORCID: https://orcid.org/0000-0001-5192-2273)
- Bryan Fellman (ORCID: https://orcid.org/0000-0002-1810-5762)
- Nicole D. Fleming (ORCID: https://orcid.org/0000-0003-1785-4072)
- Xun Xu (ORCID: https://orcid.org/0000-0002-0504-362X)
- Mohammad Mohammad (ORCID: https://orcid.org/0000-0003-2623-6364)
- Anil K. Sood (ORCID: https://orcid.org/0000-0003-4242-1762)
- Kristin Anderson
- Ljiljana Milojevic
- Richard A. Hajek
- Diane Bodurka
- Amma Asare
- Hai Tran
- Margaret B. Morgan
- Gordon B. Mills
- Jinsong Liu
- Allison L. Brodsky
- Robert L. Coleman
- Pamela Soliman
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Oregon Health & Science University (US)
- Opexa Therapeutics (United States) (US)
- The US Oncology Network (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1616
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Astex Pharmaceuticals
- Ovarian Cancer Research Alliance
- MacroGenics
- Eisai
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute